Company Overview and News

 
Emerald Health Therapeutics Names DDB Canada Agency of Record

2018-04-20 globenewswire
VICTORIA, British Columbia, April 20, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“Emerald”) (TSX-V:EMH) (OTCQX:EMHTF) today announced DDB Canada’s Vancouver office its agency of record (AOR) following a national search managed by Reynolds & Fyshe. As agency of record, DDB Canada Vancouver and its integrated suite of marketing specialist disciplines, Twice, TRACKDDB, DDB Public Relations, TracyLocke Canada and Tribal Worldwide, will be providing a full range of seamlessly integrated communications services.
Upvote Downvote

 
Emerald Health Therapeutics Expands Strategic Investment in VANC

2018-04-17 globenewswire
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. (“VANC”) announced today that it has entered into a supply and distribution agreement (“Distribution Agreement”) with an affiliate of Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”), pursuant to which VANC was granted rights to sell and distribute certain proprietary endocannabinoid-supporting products in Canada to licensed pharmacies.
Upvote Downvote

 
GW Pharma's Cannabinoid-Based Epilepsy Position Continues To Strengthen

2018-04-02 seekingalpha
Childhood Epilepsy solutions are just the first phase in a range of treatments for GW Pharma.
Upvote Downvote

 
TheBaron VII: Tough Market Movement Spells Opportunity

2018-03-28 seekingalpha
The overall portfolio had a weak month due mainly to one company's continued share price weakness, with slight moves downwards in most of the portfolio.
Upvote Downvote

 
DMG CEO Report Q1

2018-03-27 globenewswire
DMG Blockchain Solutions Announces Q1 Progress: Cryptocoin Mining Service Capacity Sells Out, Up to a 85 Megawatt Mine Construction Underway, Closes First M&A Deal, Strategic Partnerships Inked
Upvote Downvote

 
DMG CEO Report Q1

2018-03-21 globenewswire
DMG Blockchain Solutions Announces Q1 Progress: Cryptocoin Mining Service Capacity Sells Out, Up to a 85 Megawatt Mine Construction Underway, Closes First M&A Deal, Strategic Partnerships Inked
Upvote Downvote

 
Must-Know Updates from the Cannabis Sector Last Week

2018-03-05 editors.aws.marketrealist
Last week, most of the cannabis sector ETFs ended in the positive territory. The Evolve Marijuana ETF (SEED) ended last week 2.9% higher from the closing on February 23 to the closing on March 2.
Upvote Downvote

 
Can Supreme Cannabis Differentiate With Branding And B2B Model?

2018-02-26 seekingalpha
As demand for medical and recreational cannabis increases, the overall industry has engaged in different strategies and tactics in an attempt to differentiate from one another, so the sector isn't considered a commodity business that competes only on price. Under that scenario there wouldn't be many profitable producers.
Upvote Downvote

 
Key Developments in the Cannabis Sector Last Week

2018-02-20 editors.aws.marketrealist
The week ending February 16 wasn’t so positive for marijuana stocks even though the broader market indexes ended in the positive territory. The S&P 500 Index (SPY) rose 4% from the closing on February 9 to the closing on February 16. Over this period, the TSX (Toronto Stock Exchange) 300 Composite Index rose 3%. However, some of the major marijuana stocks took a deep dive, and the marijuana ETFs also ended in the negative territory.
Upvote Downvote

 
Pot Pharm: Booming Canada weed sector plots next-wave medicines

2018-02-16 cbc.ca
Canopy Growth Corp., one of the world's biggest medical marijuana producers, now wants to take on the world's pharmaceutical giants.
Upvote Downvote

 
RPT-INSIGHT-Pot Pharm: Booming Canada weed sector plots next-wave medicines

2018-02-16 reuters
TORONTO, Feb 16 (Reuters) - Canopy Growth Corp, one of the world’s biggest medical marijuana producers, now wants to take on the world’s pharmaceutical giants.
Upvote Downvote

 
Pot Pharm: Booming Canada weed sector plots next-wave medicines

2018-02-16 reuters
TORONTO (Reuters) - Canopy Growth Corp, one of the world’s biggest medical marijuana producers, now wants to take on the world’s pharmaceutical giants.
Upvote Downvote

1
Canada's Supreme Cannabis Play

2018-02-08 seekingalpha
No one really knows the size of the Canadian cannabis market once legalized, estimates vary from $2.4 billion - $8 billion USD.
Upvote Downvote

 
Analyst Ratings and Price Targets for Major Cannabis Stocks

2018-02-08 editors.aws.marketrealist
In Why Cannabis Stocks Fell in the Week Ended February 2, we discussed how last week’s marketwide shock also negatively impacted cannabis stocks. We also looked at the valuation multiples in the cannabis industry and how they looked stretched.
Upvote Downvote

TBQBF: Emerald Health Therapeutics (TSXV:EMH) Analysis and Research Report

2017-12-14 - Asif

Emerald Health Therapeutics, Inc. was incorporated pursuant to the Business Corporations Act (British Columbia) on July 31, 2007 as Firebird Capital Partners Inc. and changed its name to Firebird Energy Inc. in December 2012. On September 4, 2014, the Company completed the acquisition of all the issued and outstanding common shares of Thunderbird Biomedical Inc. (“Thunderbird”), by way of a reverse takeover (the “Transaction”) under the rules of the TSX Venture Exchange (the “TSXV”) and concurrently changed its name to T-Bird Pharma, Inc. At that time, Thunderbird became a wholly-owned subsidiary of T-Bird. In June 2015, the Company changed its name to Emerald Health Therapeutics, Inc. and Thunderbird changed its name to Emerald Health Botanicals Inc. (“Botanicals”). The Company is a publicly traded company with headquarters in Victoria, British Columbia, Canada. Common shares of the Company (the “Common Shares”) are listed on the TSXV under the trading symbol “EMH”. The Company is ...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 29102R106